Sunday, December 9 - Plenary Sessions and Scientific Presentations

Oncolink Features

Find My Cancer Drug

Changes in Endogenous Erythropoietin and the Pharmacokinetics of Darbepoetin Alfa in Patients with Non-myeloid Malignancies Receiving or Not Receiving Chemotherapy Presenter: A.C. Heatherington Presenter's Affiliation: Type of Session: Poster Background Several studies have reported an increase in endogenous erythropoietin (EPO) after chemotherapy, however, there is no published data on the...
Characterization of Erythroid Differentiation Related Factor (EDRF), a GATA-1 Regulated Molecular Chaperone for á-globin Protein Presenter: Yi Kong Presenter's Affiliation: Children's Hospital of Philadelphia Type of Session: Plenary Background Molecular chaperone proteins are believed to exist which coordinate the exquisitely controlled translation and folding of...
Combining an Allogeneic Graft-Vs-Myeloma Effect with High-Dose Autologous Stem Cell Rescue in the Treatment of Multiple Myeloma Presenter: David G. Maloney Presenter's Affiliation: Fred Hutchinson Cancer Research Center, Seatle, WA Type of Session: Plenary Background Myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for Multiple Myeloma has been...
Darbepoetin Alfa Administered Every 1 or 2 Weeks Alleviates Anemia in Patients With Solid Tumors Presenter: John Glaspy Presenter's Affiliation: UCLAType of Session: Poster Background One of the most problematic side-effects of chemotherapy is anemia, or a decreased red blood cell count. Not only can anemia cause shortness of breath and...
Development and Validation of the FACT-Neutropenia Presenter: Elizabeth A. Calhoun Presenter's Affiliation: Northwestern University Background The Functional Assessment of Cancer Therapy (FACT)is a series of validated scales designed to measure quality of life (QOL). It consists of a general...
Dose Response of Darbepoetin Alfa Is Similar in Anemic Patients with Solid Tumors or Lymphoproliferative Malignancies. Presenter: Michael Hedenus Presenter's Affiliation: Sundsvall, Sweden Type of Session: Poster Background One of the most problematic side-effects of chemotherapy is anemia, or a decreased red blood cell count. Not only can anemia cause...
Expression Profiling of Pediatric Acute Lymphoblastic Leukemia (ALL) Blasts at Diagnosis Accurately Predicts both the Risk of Relapse and of Developing Therapy-Induced ALL Presenter: E. Yeoh PresentAer's Affiliation: National University of Singapore Type of Session: Plenary Background Pediatric patients with ALL (PALL) are typically stratified into risk groups to help direct therapy. 80% of patients are now...
HRI is necessary for Regulation of Globin Translation and Survival of Erythroid Precursors in Iron-Deficiency Presenter: An-Ping Han Presenter's Affiliation: MIT Type of Session: Plenary Background The balanced production of heme and globin chains during erythroid cell development results in the production of 250 million hemoglobin molecules per red...
Molecular and Chromosomal Characterization of Resistance in CML Patients after STI-571 (Glivec) Therapy Presenter: Andreas Hochhaus Presenter's Affiliation: Universitat Heidelberg Type of Session: Plenary Background STI-571 is a promising new treatment modality for CML which functions by potent and selective inhibition of the BCR-ABL oncogene. ...
Monitoring the Anti-Tumor Activity of Expanded CD8+ NKT Cells After Allogeneic Bone Marrow Transplantation Using Bioluminescent Imaging Presenter: Matthias Edinger Presenter's Affiliation: Stanford University School of Medicine Type of Session: Plenary Background Biolumiscent imaging is an imaging technique that allows the visualization of labeled cells within a living animal. ...
Structure of a von Willebrand Factor Cleaving Protease, an ADAMTS Protease Involved in Thrombotic Thrombocytopenic Purpura (TTP) Presenter: Dominic Chung Presenter's Affiliation: Type of Session: Plenary Background Von Willebrand Factor Cleaving Protease (VWFCP) is a plasma metalloprotease that cleaves von Willebrand Factor multimer to smaller sizes. Deficiency of this...
The Epidemiology and Economics of Neutropenia in Hospitalized Adult Cancer Patients: Data From the University HealthSystem Consortium Presenter: Gary H. Lyman Presenter's Affiliation: Albany Medical College Type of Session: Poster Background Neutropenia is a common toxicity of conventional chemotherapy accounting for a large percentage of inpatient hospital expenditures,...
The Pharmacokinetics of Darbopoetin Alpha Administered Subcutaneously in Patients with Non-Myeloid Malignancies Receiving Multicycle Chemotherapy Presenter: A. C. Heatherington Presenter's Affiliation: Amgen, Inc. Type of Session: Poster Background Darbopoetin Alpha (NESP, Aranesp) is a novel synthetic variant of rHuEPO possesing 2 additional consensus N-linked carbohydrate groups. ...